Ieq Capital LLC Sells 10,346 Shares of Edwards Lifesciences Co. (NYSE:EW)

Ieq Capital LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 18.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,161 shares of the medical research company’s stock after selling 10,346 shares during the quarter. Ieq Capital LLC’s holdings in Edwards Lifesciences were worth $3,417,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Abacus Planning Group Inc. boosted its position in Edwards Lifesciences by 0.3% during the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after purchasing an additional 140 shares during the period. Bowman & Co S.C. boosted its position in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock valued at $924,000 after acquiring an additional 148 shares during the period. Pegasus Asset Management Inc. boosted its position in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after acquiring an additional 159 shares during the period. Mount Yale Investment Advisors LLC boosted its position in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after acquiring an additional 162 shares during the period. Finally, JFS Wealth Advisors LLC boosted its position in shares of Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares during the period. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EW. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research report on Thursday, February 13th. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $79.95.

Insider Activity

In other news, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $73.25 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a fifty day moving average price of $72.85 and a two-hundred day moving average price of $70.00. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The firm has a market capitalization of $43.20 billion, a P/E ratio of 10.51, a P/E/G ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.